{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:36:30Z","timestamp":1791275790440,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T00:00:00Z","timestamp":1342742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s00125-012-2654-6","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T12:23:59Z","timestamp":1342700639000},"page":"2747-2758","source":"Crossref","is-referenced-by-count":64,"title":["Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity\/diabetes"],"prefix":"10.1007","volume":"55","author":[{"given":"N.","family":"Irwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Frizelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. C.","family":"Moffett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. P. M.","family":"O\u2019Harte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,7,20]]},"reference":[{"key":"2654_CR1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1152\/ajplegacy.1928.86.3.599","volume":"65","author":"AC Ivy","year":"1928","unstructured":"Ivy AC, Oldberg E (1928) A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 65:599\u2013613","journal-title":"Am J Physiol"},{"key":"2654_CR2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.bjp.0707390","volume":"152","author":"I Verbaeys","year":"2007","unstructured":"Verbaeys I, Le\u00f3n-Tamariz F, Buyse J, de Cuyper M, Pottel H, van Boven M et al (2007) PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement. Br J Pharmacol 152:396\u2013403","journal-title":"Br J Pharmacol"},{"key":"2654_CR3","first-page":"G53","volume":"256","author":"P Cantor","year":"1989","unstructured":"Cantor P, Rehfeld JF (1989) Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus. Am J Physiol 256:G53\u2013G61","journal-title":"Am J Physiol"},{"key":"2654_CR4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2174\/156802607780960483","volume":"7","author":"JF Rehfeld","year":"2007","unstructured":"Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV (2007) The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 7:1154\u20131165","journal-title":"Curr Top Med Chem"},{"key":"2654_CR5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1152\/physrev.00014.2005","volume":"86","author":"M Dufresne","year":"2006","unstructured":"Dufresne M, Seva C, Fourmy D (2006) Cholecystokinin and gastrin receptors. Physiol Rev 86:805\u2013847","journal-title":"Physiol Rev"},{"key":"2654_CR6","first-page":"175","volume-title":"Gut peptides biochemistry and physiology","author":"RA Liddle","year":"1994","unstructured":"Liddle RA (1994) Cholecystokinin. In: Walsh JH, Dockray GJ (eds) Gut peptides biochemistry and physiology. Raven, New York, pp 175\u2013216"},{"key":"2654_CR7","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/en.2010-0233","volume":"151","author":"JA Lavine","year":"2010","unstructured":"Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL et al (2010) Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology 151:3577\u20133588","journal-title":"Endocrinology"},{"key":"2654_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2174\/138920009787522124","volume":"10","author":"PR Flatt","year":"2009","unstructured":"Flatt PR, Bailey CJ, Green BD (2009) Recent advances in antidiabetic drug therapies targeting the enteroinsular axis. Curr Drug Metab 10:125\u2013137","journal-title":"Curr Drug Metab"},{"key":"2654_CR9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","volume":"297","author":"JJ Holst","year":"2009","unstructured":"Holst JJ, Vilsb\u00f8ll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297:127\u2013136","journal-title":"Mol Cell Endocrinol"},{"key":"2654_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1748-1716.2010.02235.x","volume":"201","author":"JF Rehfeld","year":"2011","unstructured":"Rehfeld JF (2011) Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf) 201:405\u2013411","journal-title":"Acta Physiol (Oxf)"},{"key":"2654_CR11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.peptides.2008.11.010","volume":"30","author":"I Verbaeys","year":"2009","unstructured":"Verbaeys I, Le\u00f3n-Tamariz F, Buyse J, Decuypere E, Pottel H, Cokelaere M (2009) Lack of tolerance development with long-term administration of PEGylated cholecystokinin. Peptides 30:699\u2013704","journal-title":"Peptides"},{"key":"2654_CR12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bjp.2008.257","volume":"155","author":"I Verbaeys","year":"2008","unstructured":"Verbaeys I, Le\u00f3n-Tamariz F, Pottel H, Decuypere E, Swennen Q, Cokelaere M (2008) PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats. Br J Pharmacol 155:417\u2013423","journal-title":"Br J Pharmacol"},{"key":"2654_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000090310","volume":"24","author":"SA Peter","year":"2006","unstructured":"Peter SA, D'Amato M, Beglinger C (2006) CCK1 antagonists: are they ready for clinical use? Dig Dis 24:70\u201382","journal-title":"Dig Dis"},{"key":"2654_CR14","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/0016-5085(93)91070-X","volume":"105","author":"P Hoffmann","year":"1993","unstructured":"Hoffmann P, Eberlein GA, Reeve JR Jr, B\u00fcnte RH, Grandt D, Goebell H et al (1993) Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs. Gastroenterology 105:1732\u20131736","journal-title":"Gastroenterology"},{"key":"2654_CR15","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0196-9781(96)00036-8","volume":"17","author":"M Migaud","year":"1996","unstructured":"Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fourni\u00e9-Zaluski MC, Roques BP (1996) The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17:601\u2013607","journal-title":"Peptides"},{"key":"2654_CR16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2337\/diabetes.47.10.1619","volume":"47","author":"FP O'Harte","year":"1998","unstructured":"O'Harte FP, Mooney MH, Kelly CM, Flatt PR (1998) Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes 47:1619\u20131624","journal-title":"Diabetes"},{"key":"2654_CR17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.bcp.2009.05.037","volume":"78","author":"BD Kerr","year":"2009","unstructured":"Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR, Gault VA (2009) Fatty acid derivatised analogs of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem Pharmacol 78:1008\u20131016","journal-title":"Biochem Pharmacol"},{"key":"2654_CR18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.2337\/diabetes.45.8.1132","volume":"45","author":"NH McClenaghan","year":"1996","unstructured":"McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YH, O'Harte FP, Yoon TW et al (1996) Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 45:1132\u20131140","journal-title":"Diabetes"},{"key":"2654_CR19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF00252768","volume":"20","author":"PR Flatt","year":"1981","unstructured":"Flatt PR, Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob\/+) mice. Diabetologia 20:573\u2013577","journal-title":"Diabetologia"},{"key":"2654_CR20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1463-1326.2010.01228.x","volume":"12","author":"IA Montgomery","year":"2010","unstructured":"Montgomery IA, Irwin N, Flatt PR (2010) Active immunization against (Pro3)GIP improves metabolic status in high-fat-fed mice. Diabetes Obes Metab 12:744\u2013751","journal-title":"Diabetes Obes Metab"},{"key":"2654_CR21","first-page":"11","volume":"6","author":"CJ Bailey","year":"1982","unstructured":"Bailey CJ, Flatt PR, Atkins TW (1982) Influence of genetic background and age on the expression of the obese hyperglycemic syndrome in Aston ob\/ob mice. Int J Obes 6:11\u201321","journal-title":"Int J Obes"},{"key":"2654_CR22","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/db10-0789","volume":"60","author":"CM Lo","year":"2011","unstructured":"Lo CM, Obici S, Dong HH, Haas M, Lou D, Kim DH et al (2011) Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. Diabetes 60:2000\u20132007","journal-title":"Diabetes"},{"key":"2654_CR23","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1172\/JCI43615","volume":"121","author":"S Ali","year":"2011","unstructured":"Ali S, Lamont BJ, Charron MJ, Drucker DJ (2011) Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 121:1917\u20131929","journal-title":"J Clin Invest"},{"key":"2654_CR24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1677\/JOE-10-0298","volume":"207","author":"BT Layden","year":"2010","unstructured":"Layden BT, Durai V, Newman MV, Marinelarena AM, Ahn CW, Feng G et al (2010) Regulation of pancreatic islet gene expression in mouse islets by pregnancy. J Endocrinol 207:265\u2013279","journal-title":"J Endocrinol"},{"key":"2654_CR25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/sj.ijo.0803284","volume":"30","author":"CM Mack","year":"2006","unstructured":"Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, Hoyt JA et al (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30:1332\u20131340","journal-title":"Int J Obes (Lond)"},{"key":"2654_CR26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1460-9568.2006.05016.x","volume":"24","author":"H Chen","year":"2006","unstructured":"Chen H, Kent S, Morris MJ (2006) Is the CCK2 receptor essential for normal regulation of body weight and adiposity? Eur J Neurosci 24:1427\u20131433","journal-title":"Eur J Neurosci"},{"key":"2654_CR27","first-page":"178","volume":"18","author":"J Bradwejn","year":"1993","unstructured":"Bradwejn J (1993) Neurobiological investigations into the role of cholecystokinin in panic disorder. J Psychiatry Neurosci 18:178\u2013188","journal-title":"J Psychiatry Neurosci"},{"key":"2654_CR28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neubiorev.2005.05.008","volume":"29","author":"H Wang","year":"2005","unstructured":"Wang H, Wong PT, Spiess J, Zhu YZ (2005) Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Neurosci Biobehav Rev 29:1361\u20131373","journal-title":"Neurosci Biobehav Rev"},{"key":"2654_CR29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/sj.clpt.6100272","volume":"83","author":"J Jordan","year":"2008","unstructured":"Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K et al (2008) Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther 83:281\u2013287","journal-title":"Clin Pharmacol Ther"},{"key":"2654_CR30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrg1432","volume":"5","author":"AD Roses","year":"2004","unstructured":"Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645\u2013656","journal-title":"Nat Rev Genet"},{"key":"2654_CR31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/clpt.2008.192","volume":"85","author":"AD Roses","year":"2009","unstructured":"Roses AD (2009) Stimulation of cholecystokinin-A receptors with Gl181771X a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. Clin Pharmacol Ther 85:362\u2013365","journal-title":"Clin Pharmacol Ther"},{"key":"2654_CR32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2009.06.005","volume":"124","author":"MT Neary","year":"2009","unstructured":"Neary MT, Batterham RL (2009) Gut hormones: implications for the treatment of obesity. Pharmacol Ther 124:44\u201356","journal-title":"Pharmacol Ther"},{"key":"2654_CR33","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1210\/jc.85.3.1043","volume":"85","author":"B Ahr\u00e9n","year":"2000","unstructured":"Ahr\u00e9n B, Holst JJ, Efendic S (2000) Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85:1043\u20131048","journal-title":"J Clin Endocrinol Metab"},{"key":"2654_CR34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0031-9384(78)90278-0","volume":"21","author":"S Mineka","year":"1978","unstructured":"Mineka S, Snowdon CT (1978) Inconsistency and possible habituation of CCK-induced satiety. Physiol Behav 21:65\u201372","journal-title":"Physiol Behav"},{"key":"2654_CR35","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/302703a0","volume":"302","author":"JN Crawley","year":"1983","unstructured":"Crawley JN, Beinfeld MC (1983) Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302:703\u2013706","journal-title":"Nature"},{"key":"2654_CR36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0195-6663(87)90021-3","volume":"8","author":"DB West","year":"1987","unstructured":"West DB, Greenwood MR, Marshall KA, Woods SC (1987) Lithium chloride, cholecystokinin and meal patterns: evidence that cholecystokinin suppresses meal size in rats without causing malaise. Appetite 8:221\u2013227","journal-title":"Appetite"},{"issue":"Suppl 1","key":"2654_CR37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1463-1326.2011.01457.x","volume":"13","author":"B Ahr\u00e9n","year":"2011","unstructured":"Ahr\u00e9n B (2011) The future of incretin-based therapy: novel avenues\u2013novel targets. Diabetes Obes Metab 13(Suppl 1):158\u2013166","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2654-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-012-2654-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-012-2654-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T08:05:55Z","timestamp":1561968355000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-012-2654-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,20]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["2654"],"URL":"https:\/\/doi.org\/10.1007\/s00125-012-2654-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,20]]}}}